EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC 4.0

Aspirin for the Primary Prevention of Cardiovascular Diseases in Patients with Chronic Kidney Disease: An Updated Meta-analysis

Ioannis Bellos, Smaragdi Marinaki, Pagona Lagiou, Vassiliki Benetou

American Journal of Cardiovascular Drugs · 2024

DOI: 10.1007/s40256-024-00630-y ↗

Kurz gefasst

Metaanalyse in der Zeitschrift American Journal of Cardiovascular Drugs, 2024. Verfasst von Ioannis Bellos und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, 75, Mikras Asias str.…. Hauptthemen laut MEDLINE: Aspirin, Cardiovascular Diseases, Primary Prevention, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Athens.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: Chronic kidney disease is associated with increased risk of cardiovascular diseases (CVD). This meta-analysis aims to evaluate the efficacy and safety of aspirin administered for primary prevention of CVD in patients with chronic kidney disease. METHODS: PubMed, Scopus, Web of Science, CENTRAL and Clinicaltrials.gov were systematically searched from inception to 22 June 2023. Randomized controlled trials (RCTs) and cohort studies evaluating aspirin as primary prevention of CVD in chronic kidney disease were included. Meta-analysis was conducted using random-effects models. RESULTS: Overall, 11 studies (6 RCTs and 5 cohort studies) with 24,352 patients were included. The meta-analysis of RCTs indicated that aspirin was associated with lower risk of major adverse cardiovascular events [hazard ratio (HR): 0.79; 95% confidence intervals (CI): 0.64-0.97] and higher risk of major bleeding [risk ratio (RR): 1.35; 95% CI 1.15-1.58]. Incorporating observational evidence led to statistically non-significant findings in terms of risk of both cardiovascular events (pooled HR: 0.97; 95% CI 0.75-1.25; low certainty) and major bleeding (pooled RR: 1.21; 95% CI 0.99-1.48; moderate certainty). No statistically significant differences between aspirin and placebo were observed in the outcomes of mortality, coronary heart disease, stroke and renal events. CONCLUSIONS: RCT evidence points to a possible benefit in cardiovascular event reduction from aspirin administration, at the cost of increased major bleeding risk. This finding was not confirmed when the existing observational evidence was incorporated. Further research should determine the most appropriate subpopulation of chronic kidney disease patients that would benefit the most from prophylactic aspirin therapy. REGISTRATION: The study protocol has been prospectively registered and is publicly available from: https://doi.org/10.17504/protocols.io.261ged63jv47/v1 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinCardiovascular DiseasesPrimary PreventionRenal Insufficiency, ChronicHumansHemorrhagePlatelet Aggregation InhibitorsRandomized Controlled Trials as Topic

Substanzen

AspirinPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, 75, Mikras Asias str., 115 27, Athens, Greece. bellosg@windowslive.com.
  • Department of Nephrology and Renal Transplantation, Laiko General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. bellosg@windowslive.com.
  • Department of Nephrology and Renal Transplantation, Laiko General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, 75, Mikras Asias str., 115 27, Athens, Greece.

Förderung

  • University of Athens

Zitieren

APA

Bellos, I., Marinaki, S., Lagiou, P., & Benetou, V. (2024). Aspirin for the Primary Prevention of Cardiovascular Diseases in Patients with Chronic Kidney Disease: An Updated Meta-analysis. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-024-00630-y

Vancouver

Bellos I, Marinaki S, Lagiou P, Benetou V. Aspirin for the Primary Prevention of Cardiovascular Diseases in Patients with Chronic Kidney Disease: An Updated Meta-analysis. American Journal of Cardiovascular Drugs. 2024. doi:10.1007/s40256-024-00630-y

BibTeX
@article{Bellos2024,
  author = {Bellos, Ioannis and Marinaki, Smaragdi and Lagiou, Pagona and Benetou, Vassiliki},
  title = {Aspirin for the Primary Prevention of Cardiovascular Diseases in Patients with Chronic Kidney Disease: An Updated Meta-analysis},
  journal = {American Journal of Cardiovascular Drugs},
  year = {2024},
  doi = {10.1007/s40256-024-00630-y}
}
Kostenlos starten →